01:06 , Feb 8, 2018 |  BC Extra  |  Company News

Cardio/diabetes sales drag down Sanofi earnings

On the heels of a pair of proposed multibillion dollar acquisitions, Sanofi (Euronext:SAN; NYSE:SNY) reported earnings that missed analyst forecasts as the company grapples with a decline in sales for its diabetes and cardiovascular business...
01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier Brandicourt...
16:33 , Jan 26, 2018 |  BC Week In Review  |  Company News

Sanofi acquiring Bioverativ for $11.6B

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11 on Jan. 19,...
19:50 , Jan 22, 2018 |  BC Extra  |  Company News

Sanofi acquiring Bioverativ for $11.6B

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11 on Friday before...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
02:38 , Feb 11, 2017 |  BioCentury  |  Strategy

Building Bioverativ

Biogen Inc.’s newly minted hematology spinout Bioverativ Inc. will have at least three years to build market share for its hemophilia therapies and flesh out its pipeline before gene therapies potentially hit the market. Given...
00:42 , Feb 3, 2017 |  BC Week In Review  |  Company News

Biogen, Bioverativ deal

Biogen spun out its hematology business into Bioverativ. Bioverativ's two marketed drugs, Eloctate efmoroctocog alfa for hemophilia A and Alprolix eftrenonacog alfa for hemophilia B, generated a combined $888 million in 2016 revenues. The newco also...
00:05 , Feb 2, 2017 |  BC Extra  |  Company News

Biogen hematology spinout Bioverativ launches

Biogen Inc. (NASDAQ:BIIB) spun out its hematology business into Bioverativ Inc. (NASDAQ:BIVV) as a standalone public company. Bioverativ's two marketed drugs, Eloctate efmoroctocog alfa for hemophilia A and Alprolix eftrenonacog alfa for hemophilia B, generated...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking more...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Swedish Orphan Biovitrum sales and marketing update

France, Italy, Spain and the U.K. approved national reimbursement for hemophilia A drug Elocta efmoroctocog alfa from Swedish Orphan. Swedish Orphan has rights from Biogen Inc. (NASDAQ:BIIB, Cambridge, Mass.) to the long-acting recombinant...